0001726711
false
0001726711
2023-08-18
2023-08-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): August
18, 2023
Aditxt, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-39336 |
|
82-3204328 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
737 N. Fifth Street, Suite 200 Richmond, VA |
|
23219 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (650) 870-1200
N/A
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 |
|
ADTX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On
August 18, 2023, Aditxt, Inc. (the “Company”) issued a shareholder update, a copy of which is furnished as Exhibit 99.1
hereto.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ADITXT, INC. |
|
|
|
Date: August 18, 2023 |
By: |
/s/ Amro Albanna |
|
|
Amro Albanna |
|
|
Chief Executive Officer |
Exhibit 99.1
Aditxt, Inc. (NASDAQ:
ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
RICHMOND, Va. (Aug. 18, 2023) –
Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a
global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate
the immune system, is pleased to provide an important update regarding its innovation programs
and strategic M&A initiatives.
At Aditxt, our DNA is focused on bringing some
of the most needed and promising health innovations and solutions to life in a faster, more efficient way. We believe strongly in the
power of precision medicine, precision diagnostics and monitoring, precision prevention, and precision treatment. People deserve better
than a one-size-fits-all approach to disease prevention, diagnostics, and treatments—in every area of health, including autoimmune
diseases, oncology, neurology, and viral infections.
As we near the end of the third quarter of
2023 and look ahead to 2024, we are focused on expanding our portfolio to include:
| · | 2
current programs in monitoring and treating autoimmunity and organ transplantation: Adimune
and Pearsanta. |
| · | a
human clinical trial with Mayo Clinic studying the central nervous system disorder Stiff-Person
Syndrome using our proprietary ADI-100™. |
For Q2 2023 and the first half of the Q3 2023,
we have been heavily focused on ongoing conversations around promising innovations. We also mutually agreed to terminate the non-binding
letter of intent with Natural State Genomics and Natural State Laboratories.
Since the founding of Aditxt, we have believed
that commercializing health innovations deserves a new approach driven by stakeholders. For far too long, game-changing innovations never
see the light of day. Highly promising innovations, drug molecules, therapeutics, screening devices, or pieces of hardware or software,
are tabled due to lack of critical infrastructure, expertise, and resources needed to survive and thrive—including, operations,
finance, M&A, global partnerships, content and marketing, access to labs and research facilities, and more. We believe that the Aditxt
model offers the foundation innovations needed to succeed.
Finally, Aditxt was built and designed to harness
the power of global capital markets and partners—from medical research institutions to software and hardware companies, manufacturing,
and commercialization. As we expand, so does our ability to accelerate innovation. We are committed to advancing healthcare through innovation
and precision medicine. At Aditxt, we strive to make promising innovations possible, together.
Leadership Weighs
In
“Aditxt takes a stakeholder-driven approach
to developing and deploying some of the most promising health innovations such as Pearsanta’s immune monitoring platform, and Adimune’s
immune modulation therapeutic,” says Amro Albanna, Aditxt CEO, Chairman and Co-Founder. “Our goal is to get our current programs
to reach key clinical or commercial stage and expand our portfolio of innovations to address additional markets such as oncology and
neurology.”
Aditxt Portfolio
Updates
AdimuneTM,
Inc.
Immune
modulation program
Adimune, Inc.’s immune modulation technologies
are designed to retrain the immune system to restore tolerance in autoimmune diseases and allergies, and to induce tolerance in allogeneic
skin transplantation.
Program Highlights and Next Steps
| · | Adimune
and Mayo Clinic signed a clinical trial agreement to test ADI-100™ in patients with
Stiff-Person Syndrome, a rare central nervous system autoimmune disease mediated by a target
antigen also implicated in T1D. |
| - | U.S. human trials are expected to be underway
in Q4 2023. |
| - | Mayo Clinic is currently working to enroll
15 to 20 patients and initial screenings have begun. |
| · | ADI-100™
prevented checkpoint-inhibitor-induced T1D without preventing its effectiveness in reducing
cancer tumor size, demonstrating selective upregulation of regulatory cells. |
| · | Clinical
trial applications for psoriasis and T1D are expected to be filed with the German Health
Authority in Q1 2024. |
| · | Clinical
grade manufacturing of clinical grade drug substances (DNA plasmids) has been completed
and GMP formulation of clinical grade ADI-100™, to be used for the first-in-human studies
in subjects with psoriatic lesions, is expected to be initiated. |
| · | Completed
the in-life portion of the toxicology studies. Safety data are recorded and Adimune
is awaiting immunotoxicology data. |
Leadership Weighs In
“This is an exciting time for Adimune.
ADI-100™ is now part of an investigator sponsored study at the Mayo Clinic this year in patients with Stiff-Person Syndrome, a
very severe progressive central nervous system autoimmune disorder,” says Adimune co-CEO Joachim-Friedrich Kapp, M.D.,
Ph.D. “Once the stability program is completed, we intend to finalize the CTA documents and apply for regulatory approval to perform
clinical trials in two additional indications, T1D and psoriasis. We are optimistic that the findings in the human trials will confirm
what has been established in the vast number of animal safety and efficacy studies.”
PearsantaTM,
Inc.
“Lab testing
anytime and anywhere”
Pearsanta, Inc. is committed
to building a “lab testing anytime and anywhere” model through three channels:
Traditional lab developed
tests (“LDT”s); Point of Care (“POC”) devices (i.e., “lab on a chip,”); and Direct to Consumers (“DTC”)
offerings.
Program Highlights and Next Steps
| · | Established
immune monitoring center in Richmond, VA in 2021, for centralized and decentralized lab services.
An advanced multi-spectral sensor technology platform for at-home testing is currently under
development for decentralized lab services. Market roll out for at-home testing is expected
to begin in Q2 2024 through brick-and-mortar retailers along with a DTC eCommerce online
marketing strategy coupled with social media influencers. |
| · | Continuing
to expand product pipeline, research, and development, and have wider commercial reach with
patients with a POC testing platform. |
| · | Working
to identify M&A opportunities to access new territories and markets for additional innovation
expertise in the field of genetics, products, and services to deliver Pearsanta’s “Health
by the Numbers” for improved health outcomes. |
| · | Exploring
future partnerships for the development, implementation, and distribution of a rapid PCR-based
testing platform. Rapid test results will have the potential to enable almost real-time clinical
decision making in prescribing the most appropriate treatment protocol for Covid, influenza,
respiratory syncytial virus (RSV), urinary tract infections (UTIs), sexually transmitted
Infections (STIs), strep throat, and others. |
Leadership Weighs In
“Pearsanta’s lab testing platform
is a paradigm shift in how consumers can access their healthcare on demand for immediate care,” says Ernie Lee, Head of Pearsanta.
“As an example, positive lab test results from UTIs, Covid, flu, RSV, and STIs respond most effectively when treatments are started
within a few days of symptoms. Through the platform, you could potentially be tested, see a health care provider, receive a prescription
for a medication, if one is needed, and have the prescription filled—all in one encounter.”
AdivirTM,
Inc.
Antiviral therapeutics
Adivir, Inc. is focused on catalyzing discoveries
that prevent and cure infectious diseases.
Program Highlights and Next Stage
| · | Continue
to work towards completing the transaction for the acquisition of 50 percent ownership in
G Response Aid FZCO, which includes the license to develop and commercialize 200MG Avigan®
(Favipiravir), an antiviral that may be used as a mono treatment or
in combination therapies. |
About Aditxt, Inc.
Aditxt, Inc.® (NASDAQ:
ADTX) is a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor
and modulate the immune system. Headquartered in Richmond, Virginia, with operations in Silicon Valley, California, and New York. Aditxt’s
mission of “Making Promising Innovations Possible, Together” is defined by our growing ecosystem of research institutions,
global industry partners, and shareholders who inform and inspire our mission. Aditxt’s diverse innovation portfolio includes:
Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection,
autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious
diseases; and Pearsanta™, Inc., which offers personalized immune monitoring for a wide range of health conditions, including hereditary
cancer, wounds and cardiomyopathy.
For more information, visit the Company’s
websites at www.Aditxt.com, www.Adimune.com, and www.Pearsanta.com. Follow us on LinkedIn for the latest company news.
Forward-Looking Statements
Certain statements in this press release
constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements include statements
regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the
Company's ongoing and planned product and business development; the Company’s ability to finance and execute on its strategic M&A
initiatives; the Company’s ability obtain the necessary funding and partner to commence clinical trials; the Company's intellectual
property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's
results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the Company’s ability
to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company.
Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by
these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more
fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions
of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission.
All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.
Media and Investor Relations Contact:
ir@aditxt.com
www.aditxt.com
v3.23.2
Cover
|
Aug. 18, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 18, 2023
|
Entity File Number |
001-39336
|
Entity Registrant Name |
Aditxt, Inc.
|
Entity Central Index Key |
0001726711
|
Entity Tax Identification Number |
82-3204328
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
737 N. Fifth Street, Suite 200
|
Entity Address, City or Town |
Richmond
|
Entity Address, State or Province |
VA
|
Entity Address, Postal Zip Code |
23219
|
City Area Code |
(650)
|
Local Phone Number |
870-1200
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001
|
Trading Symbol |
ADTX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024